Modality
Cell Therapy
MOA
BiTE
Target
APOC3
Pathway
Lipid Met
Myelofibrosis
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Aug 2027
Phase 2Current
NCT04854981
1,328 pts·Myelofibrosis
2022-08→2027-08·Completed
NCT05779662
917 pts·Myelofibrosis
2025-02→TBD·Recruiting
2,245 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-241.4y awayPh3 Readout· Myelofibrosis
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-08-24 · 1.4y away
Myelofibrosis
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04854981 | Phase 2/3 | Myelofibrosis | Completed | 1328 | HbA1c |
| NCT05779662 | Phase 2/3 | Myelofibrosis | Recruiting | 917 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |